Chardan Capital Forecasts Immuneering FY2025 Earnings

Immuneering Co. (NASDAQ:IMRX) – Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Immuneering in a research note issued to investors on Monday, March 24th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings of ($1.65) per share for the year. Chardan Capital has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.86) per share.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.16).

Other research analysts have also issued research reports about the company. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price target on shares of Immuneering in a research note on Friday, March 21st.

Immuneering Trading Down 1.2 %

Immuneering stock opened at $1.64 on Thursday. The firm has a market cap of $58.85 million, a P/E ratio of -0.83 and a beta of -0.32. Immuneering has a 1-year low of $1.00 and a 1-year high of $3.83. The firm has a 50-day moving average of $1.76 and a 200-day moving average of $2.00.

Institutional Trading of Immuneering

Institutional investors and hedge funds have recently bought and sold shares of the stock. Corsair Capital Management L.P. purchased a new position in Immuneering during the third quarter valued at $25,000. HighTower Advisors LLC boosted its holdings in shares of Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after acquiring an additional 9,400 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in shares of Immuneering in the 4th quarter worth $390,000. XTX Topco Ltd grew its stake in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after purchasing an additional 20,871 shares during the period. Finally, Marshall Wace LLP bought a new stake in Immuneering during the fourth quarter valued at approximately $47,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.